Author  
Place of duty  
Title   항암 치료후 발생한 중증 백혈구 감소증 ( Chemotherapy Induced Severe Neutropenia )
Publicationinfo   1993 Jan; 025(04): 601-607.
Key_word   Chemotherapy, Severe neutropenia
Full-Text  
Abstract   Myelosuppression is an inevitable consequence of the treatment with almost all chemotherapeutic agents, and neutropenia is a major contributing factor of infection and mortality in cancer petients. To assess the period of neutropenia and associated morbidity after chemotherapy in patients with solid tumor, we evaluated 29 patients from May l990 to December 1991. The results were as follows: 1) The mean WBC nadir count was 520.7+-266.4/mm(3), the mean interval from the day 1 of chemotherapy to WBC counts less than 1,000/mm(3) was 13.6+-9.6 days. 2) The mean interval from the day 1 of chematherapy to WBC counts more than 1,000/mm' was 17.6+- 6.0 days, and the mean duration of grade IV neutropenia was 5.3 2.9 days. 3) The mean platelet nadir count was 93,183+-74,952/mm(3), and the incidence of throm- bocytopenia(<100,000/mm(3)) was 59%. 4) The incidence of the febrile neutropenia was 48%, and the mean duration of febrile neutropenia was 2.9+-0.7 dyas. 5) The sources of infection were sepsis in 3 cases, urinary tract infection in 1 case and unidentifiable in others. Among the 3 patients with sepsis, 2 patients died during their febrile neutropenic period. Myelosuppression is a major complication of chemotherapy and renders the patients susceptible to fatal infection. We think that the application of supportive cares including appropriate antibiotics are necessary to reduce the mortality associated with infection and it should be considered the use of hematopoietic growth factor for reduction of severity and duration of neutropenia in the future.
저 자   한지연(Ji Youn Han),안유배(You Bae Ann),강진형(Jin Hyoung Kang),문한림(Han Lim Moon),홍영선(Young Seon Hong),김훈교(Hoon Kyo Kim),이경식(Kyung Shik Lee),김동집(Dong Jip Kim),신혜숙(Hae Sook Shin),차해선(Hai Sun Cha)